Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Table 3 Summary of adverse events, patients discontinued due to adverse events and deaths

	2 % tofacitinib BID	1 % tofacitinib BID	Vehicle BID	2 % tofacitinib QD	1 % tofacitinib QD	Vehicle QD
	N = 71	N = 70	N = 71	N = 70	N = 74	N = 74
Number of AEs	47	51	54	66	65	62
Patients with treatment-emergent AEs, n (%)	30 (42.3)	30 (42.9)	28 (39.4)	34 (48.6)	28 (37.8)	40 (54.1)
Patients with application site AEs, n (%)	4 (5.6)	0 (0.0)	4 (5.6)	8 (11.4)	7 (9.5)	12 (16.2)
Patients with SAEs, n (%)	0 (0.0)	5 (7.1)	2 (2.8)	0 (0.0)	2 (2.7)	1 (1.4)
Patients discontinued due to AEs, n (%)	0 (0.0)	1 (1.4)^a	4 (5.6)	6 (8.6)	3 (4.1)	7 (9.5)
Deaths, n (%)	0 (0.0)	1 (1.4)^a	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

^aPatient had an AE of myocardial infarction and subsequently died; the patient is counted as a discontinuation due to AE and as a death
Categories of adverse events experienced include treatment-emergent, application site and serious adverse events
AE adverse event, BID twice daily, QD once daily, SAE serious adverse event

ISSN: 1471-5945